Breaking Through Solid Tumors: UTC Therapeutics’ CAR-T Clinical Data to Be Presented at AACR 2026

Breaking Through Solid Tumors: UTC Therapeutics’ CAR-T Clinical Data to Be Presented at AACR 2026

Two pivotal CAR-T research programs were selected for presentation at AACR 2026. The company will unveil groundbreaking clinical data on a global first-in-human basis through one oral presentation and one poster presentation.

SAFETY AND PRELIMINARY EFFICACY OF A NOVEL LACO-STIM® ARMORED MESOTHELIN-TARGETED CAR-T THERAPY IN ADVANCED SOLID TUMORS

This oral presentation will report the clinical outcomes of the first circular mRNA CAR-T therapy approved for (China) Investigational New Drug (IND) status. Professor Changsong Qi, a world-renowned clinical specialist in solid tumor CAR-T therapy from Peking University Cancer Hospital, will present the complete safety and efficacy data from the Phase I clinical trial on behalf of the research team for the first time globally. This presentation marks the first systematic clinical validation of this technological platform in patients with advanced solid tumors, delivering a critical reference for the global solid tumor CAR-T research community.

FIRST-IN-HUMAN PHASE I STUDY OF UCL70802, A LACO-STIM® ARMORED ANTI-CD70 CAR-T CELL THERAPY, IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA

This poster presentation will showcase landmark clinical results from the first-in-human investigator-initiated trial (IIT) of the CD70 CART in patients with metastatic clear cell renal cell carcinoma.